Relationship between Dysplasia, p53 Protein Accumulation, DNA Ploidy, and Glut1 Overexpression in Barrett Metaplasia

References

• Phillips RW, Wong RK. Barrett’s esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 1991;20:791–16.
   PubMed Web of Science ®Google Scholar
• Falk GW, Richter JE. Reflux disease and Barrett’s esophagus. Endoscopy 1996;28:13–21.
   Web of Science ®Google Scholar
• Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett’s) esophagus. Am J Clin Pathol 1978;70:1–5.
   PubMed Web of Science ®Google Scholar
• Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR. Barrett’s esophagus. Comparison of benign and malignant cases. Ann Surg 1983;198:554–65.
   PubMed Web of Science ®Google Scholar
• Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. J Thorac Cardiovas Surg 1975;70: 826–35.
   Google Scholar
• Young JL Jr, Percy CL, Asire AJ, Berg JW, Cusano MW, Gloeckler LA, et al. Cancer incidence and mortality in the United States, 1973–77. Natl Cancer Inst Monogr 1981;57:1–187.
   Google Scholar
• Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287–9.
   Google Scholar
• Blot WJ, Devessa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update [letter]. JAMA 1993; 270: 1320.
   Google Scholar
• Streitz JM Jr, Ellis FR Jr, Gibb SP, Balogh K, Watkins E Jr. Adenocarcinoma in Barrett’s esophagus. A clinicopathologic study of 65 cases. Ann Surg 1991;213:122–5.
   PubMed Web of Science ®Google Scholar
• Paraf F, Flejou JF, Pignon JP, Fekete F, Potet F. Surgical pathology of adenocarcinoma arising in Barrett’s esophagus. Analysis of 67 cases. Am J Surg Pathol 1995;19: 183–91.
   Google Scholar
• Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813–21.
   PubMed Web of Science ®Google Scholar
• Vansandick JW, Vanlanschot JJB, Kuiken BW, Tytgat GNJ, Offerhaus GJA, Obertop H. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut 1998;43:216–22.
   PubMed Web of Science ®Google Scholar
• Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett’s oesophagus. Gut 1991; 32:1441–6.
   Google Scholar
• Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988;94:81–90.
   PubMed Web of Science ®Google Scholar
• Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol 1988;19:166–78.
   Google Scholar
• Tytgat GN. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett’s esophagus) have any real value? Endoscopy 1995;27:19–26.
   PubMed Web of Science ®Google Scholar
• Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett’s esophagus. Am J Gastroenterol 1988;83:291–4.
   PubMed Web of Science ®Google Scholar
• Streitz JM, Ellis FH, Tilden RL, Erickson RV. Endoscopic surveillance of Barretts esophagus—a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998;93:911–5.
   PubMed Web of Science ®Google Scholar
• Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of a gene for human p53 tumor antigen to band 17p13. Nature 1986;320: 84–5.
   Google Scholar
• Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the ‘hot spot’ mutant phenotypes. Cell Growth Differ 1990;1:571–80.
   PubMedGoogle Scholar
• Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett’s metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993;105:1637–42.
   PubMed Web of Science ®Google Scholar
• Younes M, Ertan A, Lechago LV, Somoano JR, Lechago J. p53 Protein accumulation is a specific marker of malignant potential in Barrett’s metaplasia. Dig Dis Sci 1997;42: 697–701.
   Google Scholar
• Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212–9.
   PubMed Web of Science ®Google Scholar
• Isselbacher KJ. Sugar and amino acid transport by cells in culture—differences between normal and malignant cells. N Engl J Med 1972;286:929–33.
   PubMed Web of Science ®Google Scholar
• Holm E, Hagmuller E, Staedt U, Schlicksieser G, Gunther H-J, Leweling H, et al. Substrate balances across colonic carcinoma in humans. Cancer Res 1995;55:1373–8.
   PubMedGoogle Scholar
• Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492–5.
   PubMed Web of Science ®Google Scholar
• Rollins BJ, Morrison ED, Usher P, Flier JS. Platelet-derived growth factor regulates glucose transporter expression. J Biol Chem 1988;263:16523–6.
   PubMed Web of Science ®Google Scholar
• Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988;263:13655–62.
   Google Scholar
• Mischoulon D, Rana B, Kotliar N, Pilch PF, Bucher NL, Farmer SR. Differential regulation of glucose transporter 1 and 2 mRNA expression by epidermal growth factor and transforming growth factor-beta in rat hepatocytes. J Cell Physiol 1992;153:288–96.
   PubMed Web of Science ®Google Scholar
• Merrall NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Sign 1993;5:667–75.
   Google Scholar
• Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223–30.
   PubMed Web of Science ®Google Scholar
• Mellanen P, Minn H, Grenman R, Harkonen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994;56:622–9.
   PubMed Web of Science ®Google Scholar
• Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993;72:2979–85.
   PubMed Web of Science ®Google Scholar
• Guenther BM, Erick MP, Maria MB. Glucose transporter proteins in human insulinomas. Ann Intern Med 1994;121: 109–12.
   PubMed Web of Science ®Google Scholar
• Nagase Y, Takata K, Modyama N, Aso Y, Murakami T, Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995;153:798–801.
   PubMed Web of Science ®Google Scholar
• Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995;15: 2895–8.
   Google Scholar
• Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 1996;2:1151–4.
   Google Scholar
• Younes M, Brown RW, Stephenson M, Gondo M, Cagle PC. Overexpression of Glutl and Glut3 in stage 1 nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80: 1046–51.
   Google Scholar
• Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56: 1164–7.
   Google Scholar
• Younes M, Ertan A, Lechago LV, et al. Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett’s metaplasia. Cancer Epidemiol Biom Preven 1997;6:303–5.
   PubMed Web of Science ®Google Scholar
• Haggitt RC. Barrett’s esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982–3.
   PubMed Web of Science ®Google Scholar
• Pindur A, Chakraborty S, Welch DG, Wheeler TM. DNA ploidy measurements in prostate cancer: differences between image analysis and flow cytometry and clinical implications. Prostate 1994;25:189–98.
   PubMed Web of Science ®Google Scholar
• Biddleston LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA. The histopathology of treated Barretts esophagus—squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239–45.
   Google Scholar
• Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Squamous islands in Barretts esophagus—what lies underneath. Am J Gastroenterol 1998;93:332–5.
   Google Scholar
• Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett’s esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1–11.
   Google Scholar
• James PD, Atkinson M. Value of DNA image cytometry in the prediction of malignant change in Barrett’s oesophagus. Gut 1989;30:899–905.
   PubMed Web of Science ®Google Scholar
• Menke-Pluymers MB, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett’s oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 1994;35:1348–51.
   Google Scholar
• Fennerty MB, Sampliner RE, Way D, Riddell R, Steinbronn K, Garewal HS. Discordance between flow cytometric abnormalities and dysplasia in Barrett’s esophagus. Gastroenterology 1989;97:815–20.
   PubMed Web of Science ®Google Scholar
• Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993;14:472–7.
   PubMedGoogle Scholar
• Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, et al. 17p allelic losses in diploid cells of patients with Barrett’s esophagus who develop aneuploidy. Cancer Res 1994; 54:2292–5.
   PubMed Web of Science ®Google Scholar
• Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, et al. p53 mutations in Barrett’s adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589–95.
   PubMed Web of Science ®Google Scholar
• Wetscher GJ, Hinder RA, Bagchi D, Hinder PR, Bagchi M, Perdikis G, et al. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg 1995;170:552–6.
   PubMed Web of Science ®Google Scholar
• Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1422–55.
   Google Scholar